Search Results
Your search for The ,The matches 34690 pages
Showing 32601 - 32650Retrospective Study Indicates Improved Disease-Free Survival for Complete Mesocolic Excision vs Conventional Surgery for Colon Cancer
In a Danish retrospective population-based study reported in The Lancet Oncology, Bertelsen et al found that complete mesocolic excision resulted in better disease-free survival compared with conventional colon resection in patients with stage I to III colon cancer. Study Details The study...
No Benefit of High- vs Standard-Dose Radiotherapy or for Addition of Cetuximab to Chemoradiation in Stage IIIA or IIIB NSCLC
As reported in The Lancet Oncology by Bradley and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or for addition of cetuximab (Erbitux) to concurrent paclitaxel-carboplatin chemoradiation in patients with...
Study Finds Fear of Cancer Can Be Either a Facilitator or Deterrent to Getting Colorectal Cancer Screenings
People who worry a lot about cancer are more likely to want to get screened for colon cancer—perhaps due to a desire for reassurance—but having a more visceral negative response to thinking about cancer acted as a deterrent to actually getting screened, according to a British study by...
Study Uncovers Range of Molecular Alterations in Head and Neck Squamous Cell Carcinomas, New Potential Drug Targets
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...
Final Survival Analysis in COU-AA-302 Shows Benefit of Adding Abiraterone to Prednisone in Chemotherapy-Naive Castration-Resistant Prostate Cancer
In the final analysis of overall survival in the COU-AA-302 trial, reported in The Lancet Oncology by Ryan et al, the addition of abiraterone acetate (Zytiga) to prednisone significantly prolonged survival in chemotherapy-naive patients with castration-resistant prostate cancer. Abiraterone had...
Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer
According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...
Pre- and Postdiagnosis Physical Activity and TV Viewing Affect Overall Survival in Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Arem et al found that increased leisure-time physical activity prior to and increased activity after colorectal cancer diagnosis were associated with improved overall survival, as was less television watching prior to diagnosis. Study ...
Supplemental New Drug Application Submitted for Carfilzomib for Relapsed Multiple Myeloma
Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at...
Age-Related Clonal Hematopoiesis Associated With Increased Risk of All-Cause Mortality, Heart Disease, and Stroke, as Well as Blood Cancer
In a study reported in The New England Journal of Medicine, Jaiswal et al found somatic mutations associated with hematologic cancers at increasing frequency with increasing age, with presence of the mutations being associated with increased risk of hematologic cancers, all-cause mortality,...
RTOG 9804 Trial Shows Reduced Local Failure With Radiotherapy After Breast-Conserving Surgery in Patients With Good-Risk DCIS
As reported in the Journal of Clinical Oncology by McCormick et al, the Radiation Therapy Oncology Group (RTOG) 9804 trial showed that radiotherapy after breast-conserving surgery reduced local failure vs observation in women with good-risk ductal carcinoma in situ (DCIS). The study was designed...
Study Finds Many Women Lack Understanding of Their Breast Cancer, Especially Minority Patients
A population-based study of women who had undergone surgery for breast cancer has found that many lacked understanding of the basic characteristics of their disease, including stage, grade, and tumor characteristics. Minority patients were less likely than white patients to have the correct...
Clonal Hematopoiesis With Somatic Mutations Increases With Age and Increases Risk of Hematologic Cancer and Mortality
In a study reported in The New England Journal of Medicine, Genovese et al found that clonal hematopoiesis with somatic mutations is increasingly common with greater age and is associated with increased risk of hematologic cancer. The presence of such clonal hematopoiesis in apparently healthy...
Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development
A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...
New Breast Exam Nearly Quadruples Detection of Invasive Breast Cancers When Added to Screening Mammography in Women With Dense Breast Tissue
A new breast imaging technique developed at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a study published by Rhodes et al in the American Journal of Roentgenology. What Is MBI? Molecular breast imaging...
Sorafenib Plus Everolimus Shows Some Activity in Progressive Unresectable High-Grade Osteosarcoma
In an Italian Sarcoma Group phase II study reported in The Lancet Oncology, Grignani et al found that the combination of sorafenib (Nexavar) and everolimus (Afinitor) was active in unresectable high-grade osteosarcoma progressing after standard treatment, but did not produce the study goal of ≥...
RTOG 9910 Trial Shows No Benefit of Longer Androgen Suppression Before Radiotherapy for Localized Prostate Cancer
As reported by Pisansky et al in the Journal of Clinical Oncology, the Radiation Therapy Oncology Group (RTOG) 9910 trial showed no benefit of extending the duration of pre–radiation therapy androgen suppression on survival or disease control among patients with localized prostate cancer....
No Utility of AJCC Stage IA vs Stage IB Designation in Breast Cancer
In a study reported in the Journal of Clinical Oncology, Mittendorf et al found no differences in recurrence-free, disease-specific, or overall survival between patients with American Joint Committee on Cancer (AJCC) stage IA breast cancer and those with stage IB disease. Estrogen receptor status...
Head and Neck Cancers in Young Adults More Likely to Be a Result of Inherited Factors
Data from 25 case-control studies and separate analyses show that head and neck cancers in young adults are more likely to occur as a result of inherited factors rather than lifestyle factors, such as smoking or drinking alcohol, according to a new study by Toporcov et al published in the...
Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
Genetic Diagnosis by Exome Sequencing Feasible for Familial Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Chubb et al found that genetic diagnosis of high-penetrance susceptibility to colorectal cancer can be achieved in a sizeable proportion of familial colorectal cancer cases via exome sequencing for germline mutations. Study Details The...
Entecavir Reduces HBV-Related Hepatitis and HBV Reactivation vs Lamivudine in Lymphoma Patients Receiving R-CHOP
In a Chinese study reported in JAMA, Huang et al found that treatment with entecavir (guanosine analog reverse transcriptase inhibitor) reduced hepatitis B virus (HBV)-related hepatitis and HBV reactivation compared with lamivudine (cytidine analog reverse transcriptase inhibitor) in HBV-positive...
Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
No Survival Benefit of Adding Erlotinib to Sorafenib in Advanced Hepatocelluar Carcinoma
In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...
TP53 Mutations May Play a Role in Treatment‑Related Acute Myeloid Leukemia and Myelodysplastic Syndrome
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
Poor Health Status More Common Among Childhood Cancer Survivors vs Siblings, With Age‑Related Increase in Prevalence
In a study in the Childhood Cancer Survivor Cohort reported in the Journal of Clinical Oncology, Hudson et al found that poor health status was more common in survivors than in siblings, with an age-related increase in prevalence particularly evident in female survivors. In the study, 22,568...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Sputum Biomarker Panel May Help Identify Which Patients With Lung Nodules Have Lung Cancer
Among patients who had an unidentifiable lung nodule detected by a chest computed tomography (CT) scan, testing sputum for a panel of three microRNA (miRNA) biomarkers successfully distinguished early-stage lung cancers from nonmalignant nodules most of the time, according to a study reported by...
Next-Generation Sequencing Uncovers Potential Genetic Drivers of Rare Breast Tumors
A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of phyllodes tumors, a rare type of breast tumor. The study offers the first comprehensive analysis of the molecular alterations at work in these tumors, according to Cani...
ASCO Announces Progress in the Development of CancerLinQ, With the First Version Due in Late 2015
The American Society of Clinical Oncology (ASCO) announced today that it will use SAP HANA®, a data management and application platform, in the development of CancerLinQ, the Society’s health information technology platform that will harness Big Data to deliver high-quality care to...
Prime-Boost Vaccine Increases Survival in Metastatic Pancreas Cancer
In a study reported in the Journal of Clinical Oncology, Le et al found that adding Listeria monocytogenes–expressing mesothelin (CRS-207) boost to GVAX pancreas vaccine priming resulted in improved overall survival in patients with previously treated metastatic pancreas adenocarcinoma....
ASCO Releases Annual Report on Progress Against Cancer and Names the Cancer Advance of the Year
ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, today, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). ASCO credits the improvements in CLL care with the...
Poor Geographic Accessibility of Advanced Cancer Clinical Trial Sites
It is estimated that approximately 2% to 7% of U.S. adult patients with cancer participate in clinical trials, and poor geographic accessibility of clinical trial sites contributes to this low participation. In a study reported in JAMA Internal Medicine, Galsky et al found that approximately 40% to ...
CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the...
Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC
In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...
Low Sentinel Node Biopsy False-Negative Rate With Immunohistochemistry After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer
In the phase II SN FNAC (Sentinel Node Biopsy Following Neoadjuvant Chemotherapy) trial, reported in the Journal of Clinical Oncology, Boileau et al found a sentinel node biopsy false-negative rate of 8.4% with mandatory use of immunohistochemistry and a sentinel node biopsy identification rate of...
Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Prolonged Sedentary Time Linked to Cancer and Other Health Risks Regardless of Exercise Habits
A meta-analysis of published studies evaluating sedentary behavior in adults and health outcomes independent of physical activity has found that sedentary activities, such as prolonged sitting watching television or using a computer, is positively associated with an increased risk for all-cause...
Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin
Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium (Abstract 234). The primary analysis ...
Phase II and III Trials Support First-Line Panitumumab in Combination With FOLFOX in Wild‑Type RAS Metastatic Colorectal Cancer
New data from the phase II PEAK and phase III PRIME studies support the first-line use of panitumumab (Vectibix) in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) in patients with wild-type RAS metastatic colorectal cancer. The study results were presented during a poster session...
Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost
A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...
Allogeneic Stem Cell Transplantation Prolongs Recurrence-Free Survival in NPM1-Mutant AML
In an analysis of the Study Alliance Leukemia (SAL) AML 2003 trial reported in the Journal of Clinical Oncology, Röllig et al found that allogeneic stem cell transplantation significantly prolonged recurrence-free survival in patients with NPM1-mutant acute myeloid leukemia (AML). NPM1...
Are Physicians Choosing Wisely When Imaging for Distant Metastases in Early-Stage Breast Cancer?
Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines, and a recommendation from ASCO to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients...
Almost Half of Women Taking Tamoxifen for Primary Prevention of Breast Cancer Discontinue Use Before 5 Years
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves....
Phase II Study Shows Activity of Paclitaxel Added to Trastuzumab/Pertuzumab in HER2-Positive Metastatic Breast Cancer
In a phase II trial reported in Journal of Clinical Oncology, Dang et al found that the addition of weekly paclitaxel to trastuzumab (Herceptin)/pertuzumab (Perjeta) produced good activity in patients with HER2-positive metastatic breast cancer. Paclitaxel may be a less toxic alternative to...
Breast Cancer Diagnoses and Survival Outcomes Vary by Race/Ethnicity
Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biologic differences, according to a study reported by Iqbal et al...
Study Finds Decreasing Rates of Primary Tumor Resection and Better Survival Among Patients With Advanced Colorectal Cancer
The annual rate of primary tumor removal for stage IV colorectal cancer has decreased since 1988, and the trend toward nonsurgical management of the disease noted in 2001 coincides with the availability of newer chemotherapy and biologic treatments, according to study reported by Hu et al in JAMA...
Anamorelin Increases Lean Body Mass in Patients With Cancer Cachexia
In an integrated analysis of two phase II trials reported in The Lancet Oncology, Garcia et al found that treatment with anamorelin, an oral ghrelin-receptor agonist with appetite-enhancing and anabolic activity, produced a gain in lean body mass in patients with cancer anorexia-cachexia syndrome. ...
Selenium Supplements Following Diagnosis of Nonmetastatic Prostate Cancer May Increase Risk of Prostate Cancer Mortality
Selenium supplementation of 140 μg/d or more after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality, according to a prospective study following 4,459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-up Study...
Metabolic Syndrome Linked With Higher Risk of Endometrial Cancer Regardless of Being Overweight or Obese
A large population-based analysis of women 65 and older in the United States diagnosed with endometrial cancer has found that women with metabolic syndrome—characterized by low HDL cholesterol, hypertension, high triglycerides, and elevated waist circumference—have an increased risk of...
Cognitive Behavioral Therapy Improves Insomnia After Cancer Treatment With No Difference in Combination With Placebo or Armodafinil
In a study reported in Journal of Clinical Oncology, Roscoe et al found that cognitive behavioral therapy combined with placebo or the wakefulness-promoting agent armodafinil (Nuvigil) had similar beneficial effects on insomnia and sleep quality in cancer survivors. Study Details In the study, 96 ...
